-+ 0.00%
-+ 0.00%
-+ 0.00%

Barinthus Bio Restructures, Prioritizes VTP-1000 For Celiac Disease With Phase 1 Data In Mid-2025, Pauses VTP-300 For Hepatitis B Pending Partner; Cuts 65% Workforce, Closes U.K. Site To Extend Cash To 2027 With $112M Reserves; Focuses U.S. Operations In Germantown

Benzinga·01/10/2025 13:07:43
Listen to the news
  • Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025
  • Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified
  • Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site
  • Future operations will be focused at the U.S. site in Germantown, Maryland

OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.